357 related articles for article (PubMed ID: 16869111)
1. Biomarkers in preclinical Alzheimer's disease.
Chong MS; Lim WS; Sahadevan S
Curr Opin Investig Drugs; 2006 Jul; 7(7):600-7. PubMed ID: 16869111
[TBL] [Abstract][Full Text] [Related]
2. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
[TBL] [Abstract][Full Text] [Related]
3. CSF biomarkers for mild cognitive impairment.
Blennow K
J Intern Med; 2004 Sep; 256(3):224-34. PubMed ID: 15324365
[TBL] [Abstract][Full Text] [Related]
4. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
5. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
[TBL] [Abstract][Full Text] [Related]
6. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.
Simonsen AH; McGuire J; Hansson O; Zetterberg H; Podust VN; Davies HA; Waldemar G; Minthon L; Blennow K
Arch Neurol; 2007 Mar; 64(3):366-70. PubMed ID: 17353378
[TBL] [Abstract][Full Text] [Related]
7. Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease.
Lanni C; Racchi M; Stanga S; Mazzini G; Ranzenigo A; Polotti R; Memo M; Govoni S; Uberti D
J Alzheimers Dis; 2010; 20(1):97-104. PubMed ID: 20164600
[TBL] [Abstract][Full Text] [Related]
8. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.
Song F; Poljak A; Smythe GA; Sachdev P
Brain Res Rev; 2009 Oct; 61(2):69-80. PubMed ID: 19464319
[TBL] [Abstract][Full Text] [Related]
9. Mild cognitive impairment: believe it or not?
Allegri RF; Glaser FB; Taragano FE; Buschke H
Int Rev Psychiatry; 2008 Aug; 20(4):357-63. PubMed ID: 18925484
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
11. Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease.
Rombouts SA; Goekoop R; Stam CJ; Barkhof F; Scheltens P
Neuroimage; 2005 Jul; 26(4):1078-85. PubMed ID: 15961047
[TBL] [Abstract][Full Text] [Related]
12. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease.
Padurariu M; Ciobica A; Hritcu L; Stoica B; Bild W; Stefanescu C
Neurosci Lett; 2010 Jan; 469(1):6-10. PubMed ID: 19914330
[TBL] [Abstract][Full Text] [Related]
13. [MCI-plus: mild cognitive impairment with rapid progression. Part II: Biomarkers and research methods].
Förstl H; Werheid K; Ulm K; Schönknecht P; Schmidt R; Pantel J; Hörr R; Gutzmann H; Gertz HJ; Frölich L; Bickel H
Dtsch Med Wochenschr; 2009 Jan; 134(3):88-91. PubMed ID: 19142839
[TBL] [Abstract][Full Text] [Related]
14. [Mild Cognitive Impairment or pre-demential Alzheimer's disease?].
Sarazin M; Dubois B
Rev Neurol (Paris); 2002; 158(10 Suppl):S30-4. PubMed ID: 12529583
[TBL] [Abstract][Full Text] [Related]
15. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?
Borroni B; Di Luca M; Padovani A
Eur J Pharmacol; 2006 Sep; 545(1):73-80. PubMed ID: 16831417
[TBL] [Abstract][Full Text] [Related]
16. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for Alzheimer's disease.
Sonnen JA; Keene CD; Montine KS; Li G; Peskind ER; Zhang J; Montine TJ
Expert Rev Neurother; 2007 Aug; 7(8):1021-8. PubMed ID: 17678497
[TBL] [Abstract][Full Text] [Related]
18. [Current topics about mild cognitive impairment (MCI)].
Yamamoto Y
Seishin Shinkeigaku Zasshi; 2011; 113(6):584-92. PubMed ID: 21815470
[TBL] [Abstract][Full Text] [Related]
19. CSF cortisol in Alzheimer's disease and mild cognitive impairment.
Popp J; Schaper K; Kölsch H; Cvetanovska G; Rommel F; Klingmüller D; Dodel R; Wüllner U; Jessen F
Neurobiol Aging; 2009 Mar; 30(3):498-500. PubMed ID: 17716786
[TBL] [Abstract][Full Text] [Related]
20. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
